Mutation screening of the thyroid peroxidase gene in a cohort of 55 Portuguese patients with congenital hypothyroidism

Carina Rodrigues, Paula Jorge, José Pires Soares, Isaura Santos, Regina Salomão, Manuela Madeira, Rui Vaz Osório and Rosário Santos

Unidade de Genética Molecular, Unidade de Consulta and Comissão Nacional de Diagnóstico Precoce, Instituto de Genética Médica Jacinto Mapalhães, Praça Pedro Nunes 88, 4099-028 Porto, Portugal and Consulta de Endocrinologia Pediátrica, Hospital de Santa Maria, Av. Prof. Egas Moniz, 1699 Lisboa Codex, Portugal

(Correspondence should be addressed to R Santos; Email: rosario.santos@igm.min-saude.pt)

Abstract

Objective: Defects in the human thyroid peroxidase (TPO) gene are reported to be one of the causes of congenital hypothyroidism (CH) due to a total iodide organification defect. The aim of the present study was to determine the nature and frequency of TPO gene mutations in patients with CH, characterised by elevated TSH levels and orthotopic thyroid gland, identified in the Portuguese National Neonatal Screening Programme.

Subjects and methods: The sample comprised 55 patients, from 53 unrelated families, with follow-up in the endocrinology clinics of the treatment centres of Porto and Lisbon. Mutation screening in the TPO gene (exons 1–17) was performed by single-strand conformational analysis followed by sequencing of fragments with abnormal migration patterns.

Results: Eight different mutations were detected in 13 patients (seven homozygotes and six compound heterozygotes). Novel mutations included three missense mutations, namely 391T→C (S131P), 1274A→G (N425S) and 2512T→A (C838S), as well as the predictable splice mutation 2748G→A (Q916Q/spl?). The undocumented polymorphism 180-47A→C was also detected.

Conclusion: The results are in accordance with previous observations confirming the genetic heterogeneity of TPO defects. The proportion of patients in which the aetiology was determined justifies the implementation of this molecular testing in our CH patients with dyshormonogenesis.

Introduction

The latest annual report by the committee of the Portuguese National Neonatal Screening Programme indicates that the incidence of congenital hypothyroidism (CH) in Portugal is approximately 1/3238 newborns (1). Prior to the implementation of this screening programme (presently with a coverage rate of around 99.5%), CH was one of the most frequent causes of mental retardation in children. CH includes different clinical entities and, in the majority of cases, is a consequence of thyroid dysgenesis, in which the gland is either absent (thyroid agenesis) or located ectopically and/or severely reduced in size (hypoplasia). It is estimated that 15% of CH cases occur as a consequence of defects in the biochemical mechanisms responsible for thyroid hormone biosynthesis (thyroid dyshormonogenesis) in which human thyroid peroxidase (TPO) plays an essential role (2). Many patients with total iodide organification defect have been shown to have mutations in the TPO gene (3–15). TPO is a membrane-linked haemoprotein located at the apical membrane of the thyroid cells; it catalyses the iodination and subsequent coupling of tyrosine residues in thyroglobulin, resulting in the synthesis of the thyroid hormones tri-iodothyronine and thyroxine (T4). The human TPO gene is located on chromosome 2p25 (16) and consists of 17 exons that span 150 kb, while the respective full-length mRNA is about 3 kb long (17). Other genes thought to be implicated in this form of CH include the thyroglobulin (TG) gene (2), the sodium symporter (NIS) gene (18), the pendrin gene (PDS) (19) and, more recently, thyroid oxidase gene 2 (THOX2) (20). In the present study, we screened for TPO gene mutations in 55 CH patients presenting elevated thyroid-stimulating hormone (TSH) levels and orthotopic thyroid gland.

Subjects and methods

Patients

Since the implementation of the National Neonatal Screening Programme in Portugal, 723 cases of CH have been detected (1). Diagnosis of CH is based on elevated TSH levels (cut-off value 20 µU/ml) and
decreased T4 levels (normal > 6.5 μg/dl), ascertained in heel puncture blood samples collected on S&S 903 filter paper (Schleicher and Schuell GmbH, Dassel, Germany) between the 4th and 7th day of life. Mutation screening was performed on a group of CH patients with elevated TSH levels at the time of diagnosis and orthotopic thyroid gland. The perchlorate discharge test, which aids in the recognition of iodide organification defects, is not routinely performed; as such, elevated plasma Tg concentrations were also considered in the selection of patients, so as to exclude cases likely to result from defects in Tg synthesis or TSH receptor inactivation. The selected 55 patients were members of 53 apparently unrelated families, none of whom had any knowledge of consanguinity. Informed consent was obtained from the patients or, in the case of minors, from their parents.

**Genomic analysis**

DNA was isolated from peripheral blood according to the salting out method (21). The 17 exonic regions of the TPO gene were amplified by PCR with primers as described previously (5). The PCR reaction mixture contained 25 μl of a 2× PCR master mix (Promega Corporation, Madison, WI, USA), 1 pmol each of forward and reverse primers, 1 μl genomic DNA (50–250 ng) and nuclease-free water to a final volume of 50 μl. The PCR reactions were performed in a 9600 thermal cycler (Applied Biosystems, Foster City, CA, USA) with an initial denaturation step of 10 min at 94°C, followed by 35 cycles consisting of denaturation at 94°C for 1 min, annealing at 57°C for 1 min and extension at 72°C for 1 min and with a final extension at 72°C for 10 min. The 18 amplicons (exon 8 subdivided into two fragments, 8A and 8B) were subjected to single-strand conformational analysis (SSCA) using both the PhastSystem (Pharmacia Biotech) in PhastGels, according to the manufacturer’s instructions, and a standard vertical electrophoresis system, on 0.5× and 1.0× MDE gels (FMC Bioproducts, Rockland, ME, USA). Gels were stained by standard silver staining methods. Fragments presenting abnormal electrophoretic mobility were sequenced using the Big Dye Terminator Kit v2.0 (Applied Biosystems) and capillary electrophoresis. Because of poor electrophoretic separation on SSCA, some fragments (8A, 8B and 11) were also sequenced in all patients. A novel mutation identified in exon 8 was further characterised by restriction analysis. This mutation creates a new restriction site for DdeI, such that the 480 bp amplicon encompassing exon 8 is cut into fragments of 322 and 158 bp (Fig. 1C). Restriction analysis with DdeI was thus used to screen 100 healthy controls, none of whom presented this base change. The patient’s mother was available for sequence analysis, and she was found to carry the new N425S mutation, while the unaffected sister was carriers of the Q660E mutation. The same duplication (1183_1186dupGGCC) was also found in the affected siblings of family 3, in heterozygosity with 1978C>T. This mutation has been described previously (3) and leads to a frameshift with a termination signal in exon 9. The same duplication (1183_1186dupGGCC) was also found in the affected siblings of family 3, in heterozygosity with 1978C>T, a documented missense mutation in exon 11 which results in a glutamine to glutamic acid substitution at amino acid position 660 (Q660E) (10). Further investigation in other members of the family revealed that the father carried the 1183_1186dupGGCC mutation, while the mother and four unaffected sisters were carriers of the Q660E mutation. The patient in family 4 was found to be heterozygous for Q660E and a novel missense mutation in exon 8, where an A to T transition at nucleotide position 1274 results in an aspargine to serine change at codon 425 (Fig. 1). This alteration creates a new restriction site for Ddel, such that the 480 bp amplicon encompassing exon 8 is cut into fragments of 322 and 158 bp (Fig. 1C). Restriction analysis with Ddel was thus used to screen 100 healthy controls, none of whom presented this base change. Only the patient’s mother was available for sequence analysis, and she was found to carry the new N425S mutation. SSCA of exon 9 revealed an aberrant conformer in patient 5a. Both parents were heterozygous for this abnormal fragment, while an unaffected sister presented only the normal migration pattern. Sequence analysis showed a homozygous, known missense mutation at

**Population studies**

To investigate whether an alteration was a causal mutation or a common polymorphic variant, population screens were carried out on 100 healthy controls, either by SSCA or by differential restriction analysis. Family co-segregation studies were performed whenever possible.

**Data analysis**

The novel predicted splice site mutation, 2748G>A, was run on the GENSCAN program which predicts the locations and exon–intron structures of genes (http://genes.mit.edu/GENSCAN.html). For the novel missense mutations, phylogenetic conservation of the amino acid sequences among the peroxidase superfamily was assessed with the aid of the CLUSTAL program (http://www.ebi.ac.uk/services/clustalw).

**Results and discussion**

**Mutation analysis of the TPO gene**

In all, eight different mutations and 15 polymorphisms were detected in this group of patients. Novel alterations included three missense and one putative splice mutation, as well as a silent A to C transversion in intron 3 (180-47A>C). In 13 of the 55 patients, deleterious mutations were identified in both alleles. Clinicopathologic and mutation data are summarised in Tables 1 and 2. Sequence analysis of exon 8 revealed a homozygous GGCC duplication at nucleotide position 1187 in two unrelated patients (1a and 2a). This mutation has been described previously (3) and leads to a frameshift with a termination signal in exon 9. The same duplication (1183_1186dupGGCC) was also found in the affected siblings of family 3, in heterozygosity with 1978C>T, a documented missense mutation in exon 11 which results in a glutamine to glutamic acid substitution at amino acid position 660 (Q660E) (10). Further investigation in other members of the family revealed that the father carried the 1183_1186dupGGCC mutation, while the mother and four unaffected sisters were carriers of the Q660E mutation. The patient in family 4 was found to be heterozygous for Q660E and a novel missense mutation in exon 8, where an A to T transition at nucleotide position 1274 results in an aspargine to serine change at codon 425 (Fig. 1). This alteration creates a new restriction site for Ddel, such that the 480 bp amplicon encompassing exon 8 is cut into fragments of 322 and 158 bp (Fig. 1C). Restriction analysis with Ddel was thus used to screen 100 healthy controls, none of whom presented this base change. Only the patient’s mother was available for sequence analysis, and she was found to carry the new N425S mutation. SSCA of exon 9 revealed an aberrant conformer in patient 5a. Both parents were heterozygous for this abnormal fragment, while an unaffected sister presented only the normal migration pattern. Sequence analysis showed a homozygous, known missense mutation at
position 1477 with a nucleotide change from G to A, resulting in a glycine to serine substitution at codon 493. Patient 6a was homozygous for the documented mutation Q660E that is also present in compound heterozygosity in the affected siblings of families 3 and 10.

In the patient of family 7, a mobility shift in exon 14 led to the identification of homozygosity for the known single base pair deletion 2422delT (11). This frameshift mutation, which results in a premature stop codon, was found in heterozygosity in both parents and in one of two unaffected brothers. Patient 8a was also heterozygous for this frameshift mutation and the novel mutation in exon 5: a T to C transition at nucleotide 391 that replaces a serine at codon 131 with a proline (S131P). Both affected siblings of family 9 were found to be homozygous for a novel missense mutation in exon 14: a T to A transition at nucleotide 2512, resulting in a cysteine to serine substitution at codon 838 (C838S). The parents were heterozygous for this mutation. Finally, two other affected siblings (family 10) were found to be compound heterozygotes for Q660E and a novel point mutation, 2748G > A, in exon 16 (Fig. 2).

**Deleterious effect of the novel identified mutations**

No thyroid tissue was available for the functional studies of the peroxidases with the four novel mutations. The deleterious effect of the missense mutations was therefore evaluated by assessing the degree of evolutionary conservation of the respective amino acids, among several human and other animal wild-type peroxidases (Table 3). This approach of multiple sequence alignment indicated that N425 and some neighbouring residues are well conserved among the peroxidase superfamily. C838 is similarly well conserved among the TPOs of different species but has no counterpart in human mieloperoxidase (MPO), lactoperoxidase (LPO) or eosinophil peroxidase (EPO), or in bovine lactoperoxidase. The region

---

**Table 1** Clinicopathological characteristics of the CH patients (ten families) with TPO mutations identified in this study.

<table>
<thead>
<tr>
<th>Family/patient</th>
<th>Sex</th>
<th>Current age (years)</th>
<th>Thyroid gland</th>
<th>TSH* (μU/ml)</th>
<th>T4* (μg/dl)</th>
<th>Tg (ng/ml)</th>
<th>Identified mutations</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/a</td>
<td>F</td>
<td>7</td>
<td>Goiter</td>
<td>215</td>
<td>0.7</td>
<td>299</td>
<td>[1183_1186dupGGCC] + [1183_1186dupGGCC]</td>
</tr>
<tr>
<td>2/a</td>
<td>F</td>
<td>2</td>
<td>Goiter</td>
<td>195</td>
<td>2.9</td>
<td>955</td>
<td>[1183_1186dupGGCC] + [1183_1186dupGGCC]</td>
</tr>
<tr>
<td>3/a</td>
<td>F</td>
<td>32</td>
<td>Goiter</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>[1183_1186dupGGCC] + [1978C &gt; G]</td>
</tr>
<tr>
<td>3/b</td>
<td>F</td>
<td>13</td>
<td>Goiter</td>
<td>235</td>
<td>1.9</td>
<td>79.7</td>
<td>[1183_1186dupGGCC] + [1978C &gt; G]</td>
</tr>
<tr>
<td>4/a</td>
<td>F</td>
<td>19</td>
<td>Goiter</td>
<td>81</td>
<td>3.6</td>
<td>ND</td>
<td>[1274A &gt; G] + [1978C &gt; G]</td>
</tr>
<tr>
<td>5/a</td>
<td>M</td>
<td>11</td>
<td>Goiter</td>
<td>109.6</td>
<td>1.2</td>
<td>1344</td>
<td>[1477G &gt; A] + [1477G &gt; A]</td>
</tr>
<tr>
<td>6/a</td>
<td>F</td>
<td>5</td>
<td>Goiter</td>
<td>285</td>
<td>2.8</td>
<td>731</td>
<td>[1978C &gt; G] + [1978C &gt; G]</td>
</tr>
<tr>
<td>7/a</td>
<td>F</td>
<td>18</td>
<td>Goiter</td>
<td>192</td>
<td>0.6</td>
<td>ND</td>
<td>[2422delT] + [2422delT]</td>
</tr>
<tr>
<td>8/a</td>
<td>M</td>
<td>3</td>
<td>Goiter</td>
<td>258</td>
<td>0.5</td>
<td>416</td>
<td>[2422delT] + [391T &gt; C]</td>
</tr>
<tr>
<td>9/a</td>
<td>M</td>
<td>5</td>
<td>Goiter</td>
<td>328</td>
<td>2.9</td>
<td>2356</td>
<td>[2512T &gt; A] + [2512T &gt; A]</td>
</tr>
<tr>
<td>9/b</td>
<td>M</td>
<td>5</td>
<td>Goiter</td>
<td>378</td>
<td>1.8</td>
<td>1758</td>
<td>[2512T &gt; A] + [2512T &gt; A]</td>
</tr>
<tr>
<td>10/a</td>
<td>F</td>
<td>7</td>
<td>Normal</td>
<td>288</td>
<td>0.7</td>
<td>640</td>
<td>[1978C &gt; G] + [2748G &gt; A]</td>
</tr>
<tr>
<td>10/b</td>
<td>F</td>
<td>3</td>
<td>Normal</td>
<td>35.8</td>
<td>3.7</td>
<td>ND</td>
<td>[1978C &gt; G] + [2748G &gt; A]</td>
</tr>
</tbody>
</table>

Normal values: TSH < 20 μU/ml, T4 6.5–17 μg/dl, Tg 3–52 ng/ml

*The levels of T4 and TSH at the 4th–7th day of life.
ND, not determined.

---

**Table 2** Description of TPO mutations in the 13 CH patients.

<table>
<thead>
<tr>
<th>Exon</th>
<th>Mutationa</th>
<th>Effect of the mutation on protein synthesis</th>
<th>Reference</th>
<th>Frequency of mutant allelesb</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>391T &gt; C</td>
<td>S131P</td>
<td>Present study</td>
<td>1/110</td>
</tr>
<tr>
<td>8</td>
<td>1183_1186dupGGCC</td>
<td>N399fsX76</td>
<td>3</td>
<td>6/110</td>
</tr>
<tr>
<td>8</td>
<td>1274A &gt; G</td>
<td>N425S</td>
<td>Present study</td>
<td>1/110</td>
</tr>
<tr>
<td>9</td>
<td>1477G &gt; A</td>
<td>G493S</td>
<td>15</td>
<td>2/110</td>
</tr>
<tr>
<td>11</td>
<td>1978C &gt; G</td>
<td>Q660E</td>
<td>10</td>
<td>7/110</td>
</tr>
<tr>
<td>14</td>
<td>2422delT</td>
<td>C808fsX23</td>
<td>11</td>
<td>3/110</td>
</tr>
<tr>
<td>14</td>
<td>2512T &gt; A</td>
<td>C838S</td>
<td>Present study</td>
<td>4/110</td>
</tr>
<tr>
<td>16</td>
<td>2748G &gt; A</td>
<td>Spl?</td>
<td>Present study</td>
<td>1/110</td>
</tr>
</tbody>
</table>

*The first A in the TPO start codon considered as position 1.

bFrequency amongst the 55 patients (110 alleles).

---

www.eje-online.org
encoded by exons 8, 9 and 10 is thought to be the catalytic centre of the TPO protein and several deleterious mutations in these exons have been reported (5–7, 11, 12, 15). The missense mutation N425S described here also falls within this domain. An acidic to neutral amino acid change is likely to influence the electron transfer environment and consequently the enzymatic activity of the protein. Besides the membrane spanning region encoded by exon 15 (7), little is known about the carboxyl terminus of TPO, where the relationship between function and structure is poorly understood. Mutations in this area have been reported in several patients with severe thyroid function (3, 5, 7, 9, 12–15). The region encoded by exon 14 bears significant similarities to the epidermal growth factor (EGF)-like potential calcium binding domain (15), where there are three disulphide bonds, one of which is formed between residues C825 and C838. The latter is precisely the residue which is altered in the novel mutation described here (C838S). The substitution of cysteine by serine disables the formation of the disulphide bond.

Table 3 Comparison of amino acid sequences among various peroxidases coincident with mutations N425S and C838S.

<table>
<thead>
<tr>
<th>Mutant TPO</th>
<th>KAQLS425AHW</th>
<th>GRTS838VDS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human TPO</td>
<td>KA LN425 AHW</td>
<td>GRT C838 VDS</td>
</tr>
<tr>
<td>Pig TPO</td>
<td>KA LN424 AHW</td>
<td>GRT C837 VDA</td>
</tr>
<tr>
<td>Mouse TPO</td>
<td>KA IN413 KHW</td>
<td>GKT C926 IDS</td>
</tr>
<tr>
<td>Rat TPO</td>
<td>KA IN413 THW</td>
<td>GKT C926 IDS</td>
</tr>
<tr>
<td>Human MPO</td>
<td>KS LN434 PRW</td>
<td>*</td>
</tr>
<tr>
<td>Human LPO</td>
<td>KRLN401P OW</td>
<td>*</td>
</tr>
<tr>
<td>Bovine LPO</td>
<td>KKLN401 P OW</td>
<td>*</td>
</tr>
<tr>
<td>Human EPO</td>
<td>RRLN406 PRW</td>
<td>*</td>
</tr>
</tbody>
</table>

* No C838 counterpart found in these peroxidases. Highly conserved amino acids are expressed in bold.
bond and may thus disrupt the tertiary structure of the EGF-like potential calcium-binding domain. The novel mutation S131P, identified in exon 5, is likely to disrupt the potential glycosylation site at N129 (29), since the acceptor sequence required for N-glycosylation, namely N-X-S/T is modified to N-X-P. Studies have shown that N-glycans play an essential role in the correct folding, intracellular trafficking and activity of TPO (30). The novel mutation identified in exon 16 (2748G > A) is located at position −1 of the 5′ (donor) consensus splice site. Krawczak et al. (28) have reported a 97% consensus value for this residue in a similar sequence context. The GENSCAN program (31), that is designed to predict complete gene structures in genomic sequences, attributes a log-odds score of −20 for splicing with this base change, providing further evidence that the mutation abolishes splice site recognition. In all four cases, cosegregation analyses were consistent with a causal nature of the new mutations. Moreover, they were not detected in 100 healthy controls (200 alleles), as opposed to the hitherto undocumented polymorphism 180-47A > C, which was found in 19% of the normal control alleles.

**General remarks**

In the 13 patients with TPO mutations, the most prevalent mutation was Q660E, previously reported in a Brazilian patient (10). It was found in a homozygous state in patient 6 and in compound heterozygosity in patients 3a, 3b, 4a, 10a and 10b. A similar prevalence was noted for the 1183_1186dupG GCC mutation (six alleles of the 13 patients with TPO mutations), also reported to be the most prevalent among Dutch patients (11). The severity of these two mutations is evident in family 3 where the older sibling 3a, who had not received L-thyroxine therapy, was severely affected with mental retardation. In the same line of reasoning, one may speculate that the novel predictive splice mutation described here (2748G > A) is somewhat milder, since, in contrast with the other patients, neither affected sibling in family 10 presented goiter. Analysis of human TPO mRNA in these patients would help to elucidate the consequence of the splicing error (exon skipping and/or resort to cryptic splice sites, and resulting reading frame). This is the first molecular characterisation ever performed in a cohort of Portuguese CH patients in order to establish the aetiology of CH due to a dyshormonogenic defect. The exceptionally large proportion of patients found to have TPO mutations (approximately 24% of our sample) justifies the implementation of routine molecular testing in our CH neonates, with immediate benefits in terms of counselling and monitoring of future pregnancies, and with the foreseeable future benefit of aetiology-based differential treatment.

**Acknowledgements**

The authors would like to thank the families who gave their consent and collaborated in this study and the staff of the Neonatal Screening Laboratory for providing the original screening data of the patients. This work was supported by the Comissão de Fomento da Investigação em Cuidados da Saúde of the Portuguese Ministry of Health (project no. 163/99, Edital no. 898/98).

**References**


Received 28 June 2004
Accepted 8 October 2004